Scott Floyd, MD
Enriched profileGary Hock and Lyn Proctor Associate Professor of Radiation Oncology · Duke University
Scott Floyd is Gary Hock and Lyn Proctor Associate Professor of Radiation Oncology at Duke University. OpenAlex indexes 206 publications with 4,071 citations (h-index 28); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.
Data verified 25 Oct 2026
Overview
Updated 28 Oct 2026
Scott R. Floyd, MD, PHD, is Gary Hock and Lyn Proctor Associate Professor of Radiation Oncology at Duke University. The public record shows 206 publications with 4,071 citations (h-index 28), centered on Brain Metastases and Treatment, Glioma Diagnosis and Treatment, Management of metastatic bone disease. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 1 companies, 5 NIH-funded awards (2019–2024).
- Most recent indexed publication: 2026 · bioRxiv
- Top research focus: Brain Metastases and Treatment
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 28 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 56.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 28 Oct 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases
Sponsor: Duke University
Industry payments
Updated 28 Oct 2026
1 company reported payments to CMS in program years 2023–2023. These are public disclosures, not judgments. The latest:
- Zap Surgical Systems, Inc.Program year20232 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
100%Corticosteroid100%Dexamethasone100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 28 Oct 2026
5 NIH research awards on record, funded 2019–2024 per NIH RePORTER. The latest:
- A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform
Univ of North Carolina Chapel Hill
FY2024$1,117,537U01TR003715 - Exploring synthetic lethality with a novel very high energy electron FLASH radiation beam
Duke University
FY2024$413,971R21CA286097 - A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform
Univ of North Carolina Chapel Hill
FY2023$1,135,383U01TR003715
Congress activity
Updated 28 Oct 2026
43 congress contributions (2004–2026) across ASCO, ASTRO per OpenAlex. The most recent:
- A Novel Therapeutic Approach Using citVIM-specific CAR-T cells and Radiotherapy to Target NSCLC and Pancreatic Cancer Cells
ASTRO Annual Meeting
ASTRO2026Co-author - Federated Deep Ensemble Learning for MRI-Based Brain Metastasis Segmentation: An International Multi-Center Development
ASTRO Annual Meeting
ASTRO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 28 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Ablative radiotherapy improves survival but does not cure autochthonous mouse models of prostate and colorectal cancer.
Communications medicine
Article2023
Most-cited works
by citation count (OpenAlex)- 01Generation of high curvature membranes mediated by direct endophilin bilayer interactionsArticle603 citations2001
- 02Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancersArticle536 citations2015
- 03
- 04The bromodomain protein Brd4 insulates chromatin from DNA damage signallingArticle330 citations2013
- 05B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheresArticle184 citations2019
Network
Updated 28 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 28 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Other
scholars.duke.edu/person/scott.floyd
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 28 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
Editorial & leadership roles
journal and society appointments- Associate Program Director
Duke Radiation Oncology Residency Program
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →radonc.duke.edu ↗ - Associate Radiation Oncology Director
Duke Center for Brain and Spine Metastases
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicalphysics.duke.edu ↗
Secondary affiliations
appointments beyond the home institution- Assistant research professor
Pharmacology and Cancer Biology, Duke University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pcb.duke.edu ↗
Media & interviews
press, podcasts and appearances- News item: "How Duke is Transforming Care for Brain and Spine Metastasis" (published July 10, 2025)
listed on his Scholars@Duke recognition page
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scholars.duke.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
Scott Antonia, MD
Duke University
Jonathan Piccini, MD
Duke University
Guy McKhann, MD
Emory University School of Medicine
Patrick Wen, MD
Dana-Farber Cancer Institute
Minesh Mehta, MD
Florida International University Herbert Wertheim College of Medicine
Timothy Cloughesy, MD
Ronald Reagan UCLA Medical Center